CoSyne Therapeutics is a drug discovery company and spin-out from academic research at Imperial College London. It was founded in 2021 by experts in neuroscience, genetics and computational analysis.

CoSyne Therapeutics is using genetic computational systems analysis to develop next generation medicines at a faster rate, and for lower cost, compared to traditional methods.

The company’s first goal is to create a new class of drugs to treat the deadliest form of human brain cancer: Glioblastoma Multiforme.

The CoSyne Therapeutics platform has already identified dozens of novel vulnerabilities in GBM that can be targeted in a way that no other company or academic institution has done before.

Glioblastoma Multiforme (GBM)

“Brain tumours are awful things – they not only steal lives, they steal everything you are as a person.”

From a patient with glioblastoma multiforme.

Today, 95% of patients die within 5 years of receiving a diagnosis of GBM. There are approximately 26,400 new cases per-year in the US and Europe, including 2,500 per year in the UK. In addition to the terrible human cost to patients and families, GBM costs the UK economy approximately £1 billion per-year in NHS expenses, care needs and sick leave. To date, there are no effective treatments and the only drug currently in standard use (Temozolomide) provides a survival benefit of only 3 months. 

CoSyne Therapeutics has set out to change this. Using highly innovative methodology, our the first pilot computational drug screen has already identified 41 novel candidate drug targets. Of these, 5 of our top predictions have already been independently validated and published in Nature (Tsherniak et al. 2017), Science (Kryukov et al. 2016) and Cell (Viswanathan et al. 2018). We also re-discovered a target that is the focus of clinical trials in solid tumours (Siu et al. 2019). This hit rate is orders of magnitude greater than traditional target screening approaches.

Our Pipeline

We aim to progress our lead drug candidates through preclinical validations and early clinical trials. This will de-risk a stream of compounds to the point of phase-II trials in order to create a portfolio of attractive assets for acquisition by pharmaceutical partners.


Our development approach allows multiple stages of the drug creation process to run in parallel at high speeds. By combining innovative computational methodology, a cutting-edge biological approach and a new class of therapeutic molecules, CoSyne Therapeutics is able to develop new medicines in a way no other group has done before.